ReviewInternational journal of molecular sciences2011
Genetic and epigenetic traits as biomarkers in colorectal cancer.
Review in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Superiority of fecal carcinoembryonic antigen as diagnosis marker for adenomatous polyposis coli and asymptomatic colorectal cancer.Therapeutic advances in gastroenterology · 2021Article
- The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.Clinical epigenetics · 2019Article
- Evolving notions on immune response in colorectal cancer and their implications for biomarker development.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Review
- High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer.Oncology letters · 2018Article
- Clinical and prognosis value of the CIMP status combined with MLH1 or p16Medical oncology (Northwood, London, England) · 2017Article
- BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.Oncotarget · 2017Article
- The screening of the functional microRNA binding site SNPs in sporadic colorectal cancer genes.Cancer biology & therapy · 2017Article
- Profile of Expression of Genes Encoding Matrix Metallopeptidase 9 (MMP9), Matrix Metallopeptidase 28 (MMP28) and TIMP Metallopeptidase Inhibitor 1 (TIMP1) in Colorectal Cancer: Assessment of the Role in Diagnosis and Prognostication.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis.Journal of translational medicine · 2016Article
- Early detection of colorectal cancer: from conventional methods to novel biomarkers.Journal of cancer research and clinical oncology · 2016Review
- Article
- TGFBI protein high expression predicts poor prognosis in colorectal cancer patients.International journal of clinical and experimental pathology · 2015Article
- The structural basis for cancer treatment decisions.Oncotarget · 2014Review
- Article
- APRIL depletion induces cell cycle arrest and apoptosis through blocking TGF-β1/ERK signaling pathway in human colorectal cancer cells.Molecular and cellular biochemistry · 2013Article
- High Ran level is correlated with poor prognosis in patients with colorectal cancer.International journal of clinical oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is a major health burden, and a leading cause of cancer-related deaths in industrialized countries. The steady improvements in surgery and chemotherapy have improved survival, but the ability to identify high- and low-risk patients is still somewhat poor. Molecular biology has, over the years, given insight into basic principles of colorectal cancer initiation and development. These findings include aberrations increasing risk of tumor development, genetic changes associated with the stepwise progression of the disease, and errors predicting response to a specific treatment. Potential biomarkers in colorectal cancer are extensively studied, and how the molecular aberrations relate to clinical features. Yet, little of this knowledge has been possible to transfer into clinical practice. In this review, an overview of colorectal cancer genetics will be given, as well as how aberrations found in this tumor type are proposed as biomarkers for risk prediction, as diagnostic tools, for prognosis or prediction of treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.